Business
Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
Revenue grew 37%, driven by increased product sales and service revenueREDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Achieved revenue of $4.2 million for the first quarter of 2025Secured a significant contract with a new customer to run a 10,000-sample study in collaboration wit
About this update from Seer, Inc.
[{"type":"image","alt":"Seer, Inc.","displaySize":"","headline":null,"caption":"Seer, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":95,"url":"https://media.zenfs.com/en/globenewswire.com/54cda3f3cc4c5a0012780bcda6451a0b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WjE6r23jRNel_7Qf6Kuejw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/54cda3f3cc4c5a0012780bcda6451a0b","width":300,"height":95}},"lazy":false},{"type":"text","content":"Revenue grew 37%, driven by increased product sales and service revenue","length":71,"tagName":"p"},{"type":"text","content":"REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2025.","length":248,"tagName":"p"},{"type":"text","content":"Recent Highlights","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Achieved revenue of $4.2 million for the first quarter of 2025","length":62,"tagName":"p"}]},{"val":[{"type":"text","content":"Secured a significant contract with a new customer to run a 10,000-sample study in collaboration with Discovery Life Sciences","length":125,"tagName":"p"}]},{"val":[{"type":"text","content":"Accelerated third-party validation of platform through increasing number of customer publications, webinars, preprints and reviews","length":130,"tagName":"p"}]},{"val":[{"type":"text","content":"Ended the quarter with approximately $285 million of cash, cash equivalents and investments","length":91,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":408,"olType":false},{"type":"text","content":"“We are proud of our strong first quarter performance, especially in light of the persistent macroeconomic headwinds impacting the life sciences industry,” said Omid Farokhzad, Chair and CEO of Seer. “Momentum around the Proteograph Product Suite continues to build, and we shipped as many instruments in the first quarter of 2025 as we did in all of 2024. Our mission has always been to enable deep, unbiased proteomics at population scale, driven by our belief that the biological insights unlocked would have a meaningful impact on human health. While we expect near-term volatility to persist un...